
Press release

University Hospital Regensburg and numares present results for detection of acute kidney transplant rejection based on a simple urine test

Regensburg, Germany, November 8 2019. Early non-invasive detection of kidney rejection after transplantation was the central aim of a collaboration between Prof. Dr. Bernhard Banas, Chairman of Nephrology at the *University Hospital Regensburg (UKR)* and the medical diagnostics company, *numares*. The results of their joint clinical trial “*UMBRELLA*” were just published in *EBioMedicine* and will be presented right now at the American Society of Nephrology’s “*Kidney Week*”, being held November 5-10, in Washington DC.

Last year, in partnership, UKR and *numares* published a joint method article¹ describing a test for graft rejection based on clinical samples from UKR and the unique machine learning biomarker discovery platform pioneered by *numares*. Urine samples from patients with and without rejection were measured with nuclear magnetic resonance spectroscopy (NMR) and subsequently analyzed by machine learning algorithms in order to identify a metabolite constellation that facilitates diagnostic decisions.

The current publication in *EBioMedicine* titled “A urinary metabolite constellation to detect acute rejection in kidney allografts”² presented the results of a clinical validation study of the metabolite constellation, marketed by *numares* as *AXINON® renalTX-SCORE®*. The researchers analyzed almost 1,000 urine samples from 109 patients, which were collected over a period of one year after kidney transplantation. Afterwards, they were evaluated against kidney biopsies. The biomarker constellation was able to detect rejection up to one week prior to clinical symptoms in some cases. Overall, the study established a promising diagnostic performance.

¹ Banas MC, Neumann S, Eiglsperger J, et al. Identification of a urine metabolite constellation characteristic for kidney allograft rejection. *Metabolomics* 2018
doi: [10.1007/s11306-018-1419-8](https://doi.org/10.1007/s11306-018-1419-8)

² Banas MC, Neumann S, Pagel P, et al. A urinary metabolite constellation to detect acute rejection in kidney allografts. *EBioMedicine* 2019
doi: [10.1016/j.ebiom.2019.10.007](https://doi.org/10.1016/j.ebiom.2019.10.007)

Early warning system allows to react quickly

"We are pleased to publish the results of our work and to present them in Washington DC. We reached a true milestone on the way to a completely new rejection diagnostics and hope to successfully bring the *renaITX*-test into clinical routine practice together with *numares*", says Prof. Dr. Banas, Chairman of the Transplantation Center Regensburg and President of the *German Transplantation Society*. Dr. Miriam Banas, private lecturer and lead author of the study adds: "*numares*' allograft rejection test has several advantages. First, it allows close non-invasive kidney allograft monitoring. We get an early-warning system and can react quickly, e.g. by optimizing the therapy. Second, we naturally try to reduce the number of unnecessary biopsies with appropriate diagnostic support." *AXINON® renaITX-SCORE®* is available in the European Union as a CE-marked *in-vitro* test for use in clinical routine.

"We would like to thank the UKR and Professor Banas and his team for the successful cooperation", says Dr. Philipp Pagel, Chief Medical Officer of *numares*. "It is important for us to give a positive example of a cooperation between hospitals and industry. Regensburg is a great location for this kind of collaborative work." *numares* was founded in 2004 as a spinoff from the University of Regensburg and is located in BioPark, just one kilometer away from the UKR.

Next study already started

Based on the success of this collaborative partnership, UKR and *numares* have already taken the next step: The PARASOL study is a pan-European, multicentric, prospective observational study that evaluates the test in an extended setting. In addition to Regensburg, the partners participating in the study are located in Vienna, Prague, Grenoble and Barcelona. By the end of 2019, already more than 1,000 patients will be recruited. Initial results are expected in the first quarter of 2020.


Pictures



UKR_Banas.jpg

Professor Dr. Bernhard Banas

Picture: UKR / Klaus Völcker



Cover Niere.jpg

The results of the "UMBRELLA" study will be published at "Kidney Week" in Washington

Picture: *numares*

Image notice: UKR and *numares* - For exclusive use in the context of reporting on this press release.

About UKR

Top in medicine. Human in meeting.

The University Hospital Regensburg (UKR) treats approximately 35,500 inpatients and 154,000 outpatients annually. For this purpose, the UKR has 839 beds and 52 day hospital treatment places available (out of a total of 1,087 beds operated by the University of Regensburg's Faculty of Medicine). UKR employs more than 4,900 people in 29 human and dental clinics, polyclinics, institutes and departments. UKR is focused on high-performance medicine, especially in the fields of transplantation and intensive care medicine as well as oncological and cardiovascular diseases. For the average case severity ("Case-Mix-Index") the UKR is at the top of the German university hospitals. In addition to patient care at the

highest level, the UKR, together with the Faculty of Medicine at the University of Regensburg, is responsible for the education of around 2,150 students (human and dental medicine) and for medical research. The common aim of all employees is the optimal medical and nursing care of the patients as well as an appreciative cooperation in the team.

Contact

University Hospital Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg, Germany

Matthias Dettenhofer
Press Officer
Tel.: +49 941 944-4200
Fax: +49 941 944-4488
E-Mail: presse@ukr.de
www.ukr.de

Professor Dr. Bernhard Banas
Head of Nephrology
Tel.: +49 941-7301
nephro@ukr.de
www.ukr.de/nephrologie

About *numares*

numares, based in Regensburg, Germany, is an innovative diagnostics company that applies machine learning to metabolic data to develop advanced analytical tests for high-throughput use in clinical diagnostics and life science research. The company's *AXINON*[®] system employs nuclear magnetic resonance (NMR) spectroscopy to create a spectrum standardized by *Magnetic Group Signaling*[™] (*MGS*[®]) to evaluate metabolite constellations. *MGS*[®] is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests are an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology. More information: <https://www.numares.com/>.

Contact

numares
Julia Hertlein
Tel.: +49 941 280 949-14
E-Mail: julia.hertlein@numares.com